Stronger "mystical" experiences during ibogaine linked to bigger PTSD drops in 30 veterans

The question

Do more intense “mystical” experiences during ibogaine treatment go along with greater improvement in post-traumatic stress disorder (PTSD) symptoms?

What they did

The researchers followed 30 male veterans who had traumatic brain injury from repeated blast or combat exposure and who received magnesium-ibogaine therapy. After treatment, participants filled in the Mystical Experiences Questionnaire (MEQ30), a standard 30-item scale rating feelings such as unity, awe and transcendence during a psychedelic session. PTSD severity and resting-state EEG (a recording of the brain’s electrical rhythms) were measured before treatment, immediately after, and one month later. Statistical models tested whether MEQ30 scores tracked with changes over time.

What they found

Veterans who reported more intense mystical experiences showed larger reductions in PTSD severity, both immediately after treatment (adjusted coefficient -5.89, p < 0.001) and one month later (adjusted coefficient -4.45, p = 0.007). More intense mystical experiences were also linked to a larger drop in peak alpha frequency, a measure of the brain’s dominant resting rhythm, one month after treatment (adjusted coefficient -0.38, p = 0.006). The authors describe these as associations, not proof that the experience caused the improvement.

The fine print

This was a small group of 30 men, all veterans with brain injury from blast or combat exposure, so the results may not apply to other people. There was no placebo or comparison group and no blinding, so improvement could reflect expectation, the surrounding care, or the passage of time. Follow-up was only one month, mystical experience was rated by participants themselves after the fact, and EEG changes are a brain measure rather than a clinical outcome. This summary is based on the abstract only.

What it means

Among veterans who received magnesium-ibogaine, those who reported more intense mystical experiences also tended to report greater PTSD improvement, but the study design cannot show that one caused the other.

Evidence grade: Low. An uncontrolled analysis of 30 men treated in an open-label setting, with no comparison group and self-reported experience ratings, so it can only show associations.

This summary is based on the study’s published abstract.